When One Drug Is Not Enough : Context, Methodology, and Future Prospects in Antibacterial Synergy Testing - 03/08/19

Résumé |
Antibacterial combinations have long been used to accomplish a variety of therapeutic goals, including prevention of resistance and enhanced antimicrobial activity. In vitro synergy testing methods, including the checkerboard array, the time-kill study, diffusion assays, and pharmacokinetic/pharmacodynamic models, are used commonly in the research setting, but are not routinely performed in the clinical microbiology laboratory because of test complexity and uncertainty about their predictive value for patient outcomes. Optimized synergy testing techniques and better data on the relationship between in vitro results and clinical outcomes are needed to guide the rational use of antimicrobial combinations in the multidrug resistance era.
Le texte complet de cet article est disponible en PDF.Keywords : Antimicrobial synergy, Synergy testing, Antimicrobial susceptibility testing, Antimicrobial resistance, Checkerboard array, Time-kill assay, Hollow fiber infection model
Plan
| Disclosure Statement: TECAN (Morrisville, NC) provided an HP D300 digital dispenser and associated consumables for use by JEK's research group. Tecan had no role in article preparation or decision to publish. |
|
| Funding: Dr. T. Brennan-Krohn's synergy research is supported by a National Institute of Allergy and Infectious Diseases career development award (1K08AI132716). |
Vol 39 - N° 3
P. 345-358 - septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
